BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026)

BridgeBio Pharma has disclosed FCF Margin across 8 years of filings, most recently posting 101.46% for Q1 2026.

• FCF Margin for Q1 2026 came in at 101.46%, up 6965.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.69% (up 31700.0% YoY), and the FY2025 annual result was 89.03%, up 14605.0% from the prior year.
• FCF Margin came in at 101.46% for Q1 2026 at BridgeBio Pharma, down from 37.3% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 3445.71% in Q2 2024 to a low of 39985.21% in Q3 2022.
• The 5-year median for FCF Margin is 3321.54% (2024), against an average of 5129.51%.
• Across the five-year window, FCF Margin sank 3452348 bps in 2022 and surged 3641723 bps in 2023, its largest moves.
• BridgeBio Pharma's FCF Margin stood at 4985.56% in 2022, then sank by 44 bps to 7177.88% in 2023, then surged by 54 bps to 3321.54% in 2024, then soared by 99 bps to 37.3% in 2025, then plunged by 172 bps to 101.46% in 2026.
• The last three FCF Margin figures came in at 101.46% (Q1 2026), 37.3% (Q4 2025), and 90.3% (Q3 2025), per Business Quant data.